MedPath

COARTEM

These highlights do not include all the information needed to use COARTEM Tablets safely and effectively. See full prescribing information for COARTEM Tablets. COARTEM (artemether and lumefantrine) tablets, for oral use Initial U.S. Approval: 2009

Approved
Approval ID

7866ec19-dfac-47d4-a53f-511a12643cbf

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 2, 2023

Manufacturers
FDA

Novartis Pharmaceuticals Corporation

DUNS: 002147023

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

artemether and lumefantrine

PRODUCT DETAILS

NDC Product Code0078-0568
Application NumberNDA022268
Marketing CategoryC73594
Route of AdministrationORAL
Effective DateSeptember 15, 2017
Generic Nameartemether and lumefantrine

INGREDIENTS (9)

ARTEMETHERActive
Quantity: 20 mg in 1 1
Code: C7D6T3H22J
Classification: ACTIB
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
HYPROMELLOSESInactive
Code: 3NXW29V3WO
Classification: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8H
Classification: IACT
LUMEFANTRINEActive
Quantity: 120 mg in 1 1
Code: F38R0JR742
Classification: ACTIB
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

COARTEM - FDA Drug Approval Details